Syros Pharmaceuticals Inc
(NAS:SYRS)
$
1.66
0.04 (2.47%)
Market Cap: 44.50 Mil
Enterprise Value: 26.20 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 48/100 Syros Pharmaceuticals Inc (SYRS) Transcripts
- Q1 2024 Syros Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2024$5.43 (+7.31%)Earnings
- Q4 2023 Syros Pharmaceuticals Inc Earnings Call TranscriptMar 27, 2024$5.84 (-6.56%)Earnings
- Syros Pharmaceuticals Inc Conference Call TranscriptDec 06, 2023
- Q3 2023 Syros Pharmaceuticals Inc Earnings Call TranscriptNov 14, 2023$2.72 (+1.12%)Earnings
- Q2 2023 Syros Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2023$3.66 (-0.54%)Earnings
- Syros Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 01, 2023
- Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Q1 2023 Syros Pharmaceuticals Inc Earnings Call TranscriptMay 10, 2023$3.43 (+10.29%)Earnings
- Q4 2022 Syros Pharmaceuticals Inc Earnings Call TranscriptMar 02, 2023$3.76 (+2.73%)Earnings
- Syros Pharmaceuticals Inc to Discuss Ongoing Phase 2 SELECT-AML-1 Clinical Trial TranscriptDec 10, 2022
- Q3 2022 Syros Pharmaceuticals Inc Earnings Call TranscriptNov 14, 2022$3.66 (-8.04%)Earnings
- Q2 2022 Syros Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2022$9.27 (-4.90%)Earnings
- Syros Pharmaceuticals Inc to Acquire TYME Technologies Inc Call TranscriptJul 05, 2022
- Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- Q1 2022 Syros Pharmaceuticals Inc Earnings Call TranscriptMay 16, 2022$7.7 (-14.38%)Earnings
- Q4 2021 Syros Pharmaceuticals Inc Earnings Call TranscriptMar 15, 2022$11.1 (+3.74%)Earnings
- Q3 2021 Syros Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2021$45.6 (+3.17%)Earnings
- Syros Pharmaceuticals Inc at ESMO Congress Conference Call TranscriptSep 20, 2021
- Q2 2021 Syros Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2021$49 (+8.65%)Earnings
- Syros Pharmaceuticals Inc SY-2101 in APL-Call TranscriptJul 20, 2021
- Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed Unfit AML-Call TranscriptJun 22, 2021
- Syros Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 08, 2021
- Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed HR-MDS - Corporate Call TranscriptMay 26, 2021
- Q1 2021 Syros Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2021$55.3 (+0.91%)Earnings
- Syros Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 16, 2021
- Q4 2020 Syros Pharmaceuticals Inc Earnings Call TranscriptMar 04, 2021$79.6 (-4.33%)Earnings
- Syros Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Syros Pharmaceuticals Inc New Data From Phase 2 Clinical Trial of SY-1425 and Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML Call TranscriptDec 05, 2020
- Q3 2020 Syros Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$81.1 (-1.82%)Earnings
- Q2 2020 Syros Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$120.3 (+6.65%)Earnings
- Q1 2020 Syros Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$87.7 (-3.63%)Earnings
- Q4 2019 Syros Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2020$60.2 (-3.68%)Earnings
- Q3 2019 Syros Pharmaceuticals Inc Earnings Call TranscriptNov 12, 2019$50.2 (+0.60%)Earnings
- Syros Pharmaceuticals Inc to Announce Update on Selective CDK7 Inhibitor Portfolio Call TranscriptOct 17, 2019
- Q2 2019 Syros Pharmaceuticals Inc Earnings Call TranscriptAug 01, 2019$84.8 (+13.37%)Earnings
- Q1 2019 Syros Pharmaceuticals Inc Earnings Call TranscriptMay 01, 2019$71.7 (-0.83%)Earnings
- Q4 2018 Syros Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019$69 (-2.40%)Earnings
- 1